Capital International Inc. CA Increases Position in Amgen Inc. $AMGN

Capital International Inc. CA lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 22.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 386,784 shares of the medical research company’s stock after purchasing an additional 71,908 shares during the quarter. Amgen comprises approximately 0.9% of Capital International Inc. CA’s holdings, making the stock its 29th largest position. Capital International Inc. CA owned 0.07% of Amgen worth $109,150,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AMGN. West Family Investments Inc. raised its position in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares during the last quarter. Viawealth LLC increased its holdings in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its holdings in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. TAGStone Capital Inc. increased its holdings in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after buying an additional 32 shares in the last quarter. Finally, BBR Partners LLC raised its holdings in shares of Amgen by 0.5% during the third quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock valued at $2,008,000 after purchasing an additional 32 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

AMGN stock opened at $376.97 on Tuesday. The business has a 50-day moving average price of $354.21 and a 200 day moving average price of $323.38. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a market capitalization of $203.21 billion, a P/E ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the company posted $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s payout ratio is presently 70.84%.

Analyst Ratings Changes

Several research firms have recently weighed in on AMGN. Barclays began coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. Citigroup boosted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Mizuho increased their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Finally, Piper Sandler raised their price target on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $354.17.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.